---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-001898"
form_type: "8-K"
ticker: "AIM"
cik: "0000946644"
company_name: "AIM ImmunoTech Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T11:00:34.990869+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# AIM ImmunoTech furnishes January 2026 corporate presentation

## Summary
- Presentation filed as Exhibit 99.1 on Form 8-K dated January 12, 2026.
- No financial results or operational milestones disclosed in the filing.
- Cautionary statements reiterate risks of Ampligen development across viral, cancer, and immune indications.

## SEC filing metadata
- accession: 0001493152-26-001898
- form_type: 8-K
- ticker: AIM
- cik: 0000946644
- company_name: AIM ImmunoTech Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946644/000149315226001898/0001493152-26-001898-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946644/000149315226001898/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-001898
- JSON: https://secwatch.observer/filing/0001493152-26-001898.json
- Plain text: https://secwatch.observer/filing/0001493152-26-001898.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.